Abatacept

Red

Brand Name(s):Orencia

Indication:Severe, treatment resistant morphoea

Rheumatoid arthritis, Juvenile idiopathic arthritis & Active psoriatic arthritis in adults

Rationale:1,2,8

Considered:Apr-09

Review Date:Jul-26

Comments:
Abatacept is recommended as a treatment option through routine commissioning for adults and children 2 years and over with severe, treatment resistant morphoea within the criteria set out in the commissioning policy
July 21

NICE TA 375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Full information can be found at:http://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133
January 2016 NICE technology appraisal guidance [TA373]